Suchergebnisse - "SUBKLEWE MARION"

PubPharm (326)

91

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia

enthalten in: Infection | 2022

von Ruzicka, M. | Wurm, S. | Lindner, L. | +9

92

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia

enthalten in: Infection | 2022

von Ruzicka, M. | Wurm, S. | Lindner, L. | +9

93

CD8 T cells and antibodies drive SARS-CoV-2 evolution in chronic infection

enthalten in: ResearchSquare.com | 2022

von Khatamzas, E. | Muenchhoff, M. | Rehn, A. | +27

94

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection

enthalten in: Nature communications | 2022

von Khatamzas, E. | Antwerpen, M. | Rehn, A. | +27

95

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

enthalten in: Blood | 2022

von Philipp, N. | Kazerani, M. | Nicholls, A. | +22

CommentIn: Blood. 2022 Sep 8;140(10):1056-1058. - PMID 36074532

96

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies

enthalten in: Haematologica | 2022

von Dos Santos, D. | Rejeski, K. | Winkelmann, M. | +10

97

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

enthalten in: Blood advances | 2022

von Rejeski, K. | Burchert, A. | Iacoboni, G. | +14

98

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

enthalten in: American journal of clinical oncology | 2022

von Lewis, J. | Khaldoyanidi, S. | Britten, C. | +2

99

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

enthalten in: Blood | 2022

von Bethge, W. | Martus, P. | Schmitt, M. | +29

CommentIn: Blood. 2022 Jul 28;140(4):296-298. - PMID 35900785

100

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors

enthalten in: Journal for immunotherapy of cancer | 2022

von Stock, S. | Benmebarek, M. | Kluever, A. | +11